Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Robert C Stein; Andrea Marshall; Andreas Makris; Luke Hughes-Davies; Iain R MacPherson; Carmel Conefrey; Leila Rooshenas; Sarah E Pinder; Abeer M Shaaban; Bjørn Naume; David A Cameron; Daniel W Rea; Helena M Earl; Christopher J Poole; Peter S Hall; Georgina Dotchin; Stuart A McIntosh; Victoria Harmer; Adrienne Morgan; Bethany Shinkins; Nigel Stallard; Christopher McCabe; Jenny L Donovan; John MS Bartlett; Janet A Dunn

doi:10.1158/1538-7445.SABCS19-OT3-17-01

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Robert C Stein
, Andrea Marshall
, Andreas Makris
, Luke Hughes-Davies
, Iain R MacPherson
, Carmel Conefrey
, Leila Rooshenas
, Sarah E Pinder
, Abeer M Shaaban
, Bjørn Naume
, David A Cameron
, Daniel W Rea
, Helena M Earl
, Christopher J Poole
, Peter S Hall
, Georgina Dotchin
, Stuart A McIntosh
, Victoria Harmer
, Adrienne Morgan
, Bethany Shinkins

Nigel Stallard, Christopher McCabe, Jenny L Donovan, John MS Bartlett, Janet A Dunn

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to conference › Poster › peer-review

Original language	English
DOIs	https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-01
Publication status	Published - 14 Feb 2020
Event	42nd San Antonio Breast Cancer Symposium - San Antonio, San Antonio, United States Duration: 10 Dec 2019 → 14 Dec 2019

Conference

Conference	42nd San Antonio Breast Cancer Symposium
Abbreviated title	SABCS
Country/Territory	United States
City	San Antonio
Period	10/12/2019 → 14/12/2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1538-7445.SABCS19-OT3-17-01Licence: Unspecified

Cite this

Stein, R. C., Marshall, A., Makris, A., Hughes-Davies, L., MacPherson, I. R., Conefrey, C., Rooshenas, L., Pinder, S. E., Shaaban, A. M., Naume, B., Cameron, D. A., Rea, D. W., Earl, H. M., Poole, C. J., Hall, P. S., Dotchin, G., McIntosh, S. A., Harmer, V., Morgan, A., ... Dunn, J. A. (2020). Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. Poster session presented at 42nd San Antonio Breast Cancer Symposium, San Antonio, Texas, United States. https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-01

Stein, Robert C ; Marshall, Andrea ; Makris, Andreas et al. / Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. Poster session presented at 42nd San Antonio Breast Cancer Symposium, San Antonio, Texas, United States.

@conference{c00c1496ed214fb6afe7fecb6498533d,

title = "Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer",

author = "Stein, \{Robert C\} and Andrea Marshall and Andreas Makris and Luke Hughes-Davies and MacPherson, \{Iain R\} and Carmel Conefrey and Leila Rooshenas and Pinder, \{Sarah E\} and Shaaban, \{Abeer M\} and Bj{\o}rn Naume and Cameron, \{David A\} and Rea, \{Daniel W\} and Earl, \{Helena M\} and Poole, \{Christopher J\} and Hall, \{Peter S\} and Georgina Dotchin and McIntosh, \{Stuart A\} and Victoria Harmer and Adrienne Morgan and Bethany Shinkins and Nigel Stallard and Christopher McCabe and Donovan, \{Jenny L\} and Bartlett, \{John MS\} and Dunn, \{Janet A\}",

year = "2020",

month = feb,

day = "14",

doi = "10.1158/1538-7445.SABCS19-OT3-17-01",

language = "English",

note = "42nd San Antonio Breast Cancer Symposium, SABCS ; Conference date: 10-12-2019 Through 14-12-2019",

}

Stein, RC, Marshall, A, Makris, A, Hughes-Davies, L, MacPherson, IR, Conefrey, C, Rooshenas, L, Pinder, SE, Shaaban, AM, Naume, B, Cameron, DA, Rea, DW, Earl, HM, Poole, CJ, Hall, PS, Dotchin, G, McIntosh, SA, Harmer, V, Morgan, A, Shinkins, B, Stallard, N, McCabe, C, Donovan, JL, Bartlett, JMS & Dunn, JA 2020, 'Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer', 42nd San Antonio Breast Cancer Symposium, San Antonio, United States, 10/12/2019 - 14/12/2019. https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-01

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. / Stein, Robert C; Marshall, Andrea; Makris, Andreas et al.
2020. Poster session presented at 42nd San Antonio Breast Cancer Symposium, San Antonio, Texas, United States.

Research output: Contribution to conference › Poster › peer-review

TY - CONF

T1 - Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

AU - Stein, Robert C

AU - Marshall, Andrea

AU - Makris, Andreas

AU - Hughes-Davies, Luke

AU - MacPherson, Iain R

AU - Conefrey, Carmel

AU - Rooshenas, Leila

AU - Pinder, Sarah E

AU - Shaaban, Abeer M

AU - Naume, Bjørn

AU - Cameron, David A

AU - Rea, Daniel W

AU - Earl, Helena M

AU - Poole, Christopher J

AU - Hall, Peter S

AU - Dotchin, Georgina

AU - McIntosh, Stuart A

AU - Harmer, Victoria

AU - Morgan, Adrienne

AU - Shinkins, Bethany

AU - Stallard, Nigel

AU - McCabe, Christopher

AU - Donovan, Jenny L

AU - Bartlett, John MS

AU - Dunn, Janet A

PY - 2020/2/14

Y1 - 2020/2/14

U2 - 10.1158/1538-7445.SABCS19-OT3-17-01

DO - 10.1158/1538-7445.SABCS19-OT3-17-01

M3 - Poster

T2 - 42nd San Antonio Breast Cancer Symposium

Y2 - 10 December 2019 through 14 December 2019

ER -

Stein RC, Marshall A, Makris A, Hughes-Davies L, MacPherson IR, Conefrey C et al.. Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. 2020. Poster session presented at 42nd San Antonio Breast Cancer Symposium, San Antonio, Texas, United States. doi: 10.1158/1538-7445.SABCS19-OT3-17-01